Stock Events

Stock Events

Serina Therapeutics 

$2.03
0
+$0.16+8.56% Today

Statistics

Day High
2.03
Day Low
1.95
52W High
-
52W Low
-
Volume
1,600
Avg. Volume
-
Mkt Cap
21.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2025
Q4 2025
Next
-0.53
-0.46
-0.38
-0.31
Expected EPS
-0.44
Actual EPS
N/A

Financials

-19,894.64%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
112,000Revenue
-22.28MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SER.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that could directly compete with AgeX's regenerative medicine and cellular therapy approaches.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space, making it a direct competitor in developing therapies that could overlap with AgeX's focus on age-related diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing in the same space as AgeX by targeting genetic diseases and conditions.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing with AgeX in the development of novel therapies for genetic conditions.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, potentially competing with AgeX in the market for therapies targeting age-related diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with AgeX in the field of molecular biology and therapy development for various conditions.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics is advancing the field of CRISPR-based genetic and cellular therapies, which could compete with AgeX's therapeutic approaches.
Voyager Therapeutics
VYGR
Mkt Cap259.04M
Voyager Therapeutics focuses on the development of gene therapies for neurodegenerative diseases, potentially competing with AgeX's focus on age-related conditions.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is working on programmed cellular immunotherapies for cancer and immune disorders, which could compete with AgeX's approach to regenerative medicine and cellular therapies.

About

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Show more...
CEO
ISIN
US81751A1088

Listings

XASE
US
SER
F
DE
2BO.F
BOATS
BOATS
SER.BOATS

0 Comments

Share your thoughts

FAQ

What is Serina Therapeutics stock price today?▼
The current price of SER.BOATS is $2.03 USD — it has increased by +8.56% in the past 24 hours. Watch Serina Therapeutics stock price performance more closely on the chart.
What is Serina Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Serina Therapeutics stocks are traded under the ticker SER.BOATS.
What is Serina Therapeutics market cap?▼
Today Serina Therapeutics has the market capitalization of 21.65M
When is the next Serina Therapeutics earnings date?▼
Serina Therapeutics is going to release the next earnings report on May 19, 2026.
What were Serina Therapeutics earnings last quarter?▼
SER.BOATS earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.5 USD resulting in a +38% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Serina Therapeutics revenue for the last year?▼
Serina Therapeutics revenue for the last year amounts to 112,000 USD.
What is Serina Therapeutics net income for the last year?▼
SER.BOATS net income for the last year is -22.28M USD.
When did Serina Therapeutics complete a stock split?▼
Serina Therapeutics has not had any recent stock splits.